Fyer A J, Liebowitz M R, Gorman J M, Campeas R, Levin A, Davies S O, Goetz D, Klein D F
Am J Psychiatry. 1987 Mar;144(3):303-8. doi: 10.1176/ajp.144.3.303.
Alprazolam treatment was tapered in 17 panic patients at a rate of 10% of the starting dose every 3 days. Only four subjects completed withdrawal on schedule (4-5 weeks); four additional subjects discontinued treatment in 7-13 weeks. During withdrawal 15 patients had recurrent or increased panic attacks and nine had significant new withdrawal symptoms. Most common among the latter were malaise, weakness, insomnia, tachycardia, lightheadedness, and dizziness. None had seizures, psychosis, or significant neurological or EEG abnormalities. Results indicate that relapse and withdrawal are important considerations in the choice of alprazolam treatment for panic attacks.
对17名惊恐障碍患者逐渐减少阿普唑仑治疗剂量,每3天减少起始剂量的10%。只有4名受试者按计划完成撤药(4 - 5周);另外4名受试者在7 - 13周内停止治疗。撤药期间,15名患者出现惊恐发作复发或加重,9名患者出现明显的新撤药症状。后者中最常见的是不适、虚弱、失眠、心动过速、头晕和眩晕。无一例出现癫痫发作、精神病或明显的神经或脑电图异常。结果表明,复发和撤药是选择阿普唑仑治疗惊恐发作时的重要考虑因素。